Baxter has announced that providers at a hospital in Delaware, along with U.S. health officials, are looking into whether the deaths of two patients there were linked to a brand of Baxter's intravenous heparin product. The FDA has said the situation seems to be an isolated problem, but nobody's taking any chances. Article [1]